6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2019

Commission File Number 000-28996

ELBIT IMAGING LTD.

(Translation of Registrant’s Name into English)

5 SHIMSHON STREET, PETACH TIKVA, ISRAEL

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ 

EXHIBIT 99.1 OF THIS REPORT ON FORM 6-K IS HEREBY INCORPORATED BY REFERENCE INTO ELBIT IMAGING LTD.’S REGISTRATION STATEMENT ON FORM F-1 (REGISTRATION STATEMENTS NO. 333-194519), REGISTRATION STATEMENT ON FORM F-3 (REGISTRATION STATEMENT NO. 333-172122) AND REGISTRATION STATEMENTS ON FORM S-8 (REGISTRATION STATEMENTS NOS. 333-117509, 333-130852, 333-136684 AND 333-152820), AND TO BE A PART THEREOF FROM THE DATE ON WHICH THIS REPORT IS SUBMITTED, TO THE EXTENT NOT SUPERSEDED BY DOCUMENTS OR REPORTS SUBSEQUENTLY FILED OR FURNISHED.

CONTENTS

This Report on Form 6-K of Elbit consists of the following documents, which is attached hereto and incorporated by reference herein:

99.1. Press Release: Elbit Imaging Ltd announces data from Gamida Cell’s NAM-NK and NiCord® programs to be presented at 2019 TCT Annual Meeting.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ELBIT IMAGING LTD. (Registrant)
Date: January 28, 2019	By:	/s/ Ron Hadassi
		Ron Hadassi CEO and Chairman of the Board of Directors

2

EX-99.1

Exhibit 99.1

 

ELBIT IMAGING ANNOUNCES DATA FROM GAMIDA CELL’S NAM-NK AND

NICORD® PROGRAMS TO BE PRESENTED AT 2019 TCT ANNUAL MEETING

Tel Aviv, Israel, January 28, 2019, Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) (“Elbit”) announced today, further to its press releases dated December 3, 2018 and June 25, 2018, that Gamida Cell Ltd. (Nasdaq: GMDA) (“Gamida”), an indirect shareholding of the Company, has announced that new data from its clinical programs will be presented at the 2019 Transplantation & Cellular Therapy (TCT) Meeting of American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR) taking place in Houston, Texas, February 20–24.

During the meeting, new data will be presented from the NAM-NK and NiCord® programs, including the following¹:

1. Initial results indicating clinical response and a safe profile of the ongoing Phase I study of patients with relapsed or refractory non-Hodgkin lymphoma and multiple myeloma treated with NAM-expanded Natural Killer cells. The study is led by the University of Minnesota.

2. Results demonstrating rapid immune reconstitution in patients transplanted with NiCord, as part of a Phase I/II clinical study of hematological malignancies. The study is led by the Memorial Sloan Kettering Center.

3. Initial results indicating prompt cord engraftment and proper graft function in Phase I/II clinical study of severe aplastic anemia using NiCord (formerly: CordIn). The study is led by the National Institutes of Health.

It should be noted that patient enrollment continues in the NAM-NK study of multiple myeloma and non-Hodgkin lymphoma (NHL), and in the study of severe aplastic anemia using NiCord.

Elbit holds approximately 63% of the share capital of Elbit Medical Technologies Ltd. (TASE: EMTC-M) (approximately 41% on a fully diluted basis) which, in turn, holds approximately 2.7 million shares in Gamida, representing approximately 11% of Gamida’s outstanding share capital (approximately 8% on a fully diluted basis).

About Gamida Cell Ltd.

Gamida is engaged in the development of products for curing cancer and rare bone marrow diseases. Gamida’s products are currently being tested in clinical trials for patients with leukemia, lymph node cancer and non-malignant blood diseases. Gamida began a Phase III trial in patients with leukemia and lymph node cancer through NiCord, a drug that the FDA and EMA approved as orphan drug and which was recognized by the FDA as breakthrough treatment. It should be clarified that as of this date, the stage of development of Gamida’s products has not yet been completed and there is no certainty that the products will be marketed on a commercial basis.

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) medical industries through our indirect holdings in Insightec Ltd. and Gamida Cell Ltd.; (ii) land in India which is designated for sale (and which was initially designated for residential projects); and (iii) land in Eastern Europe which is designated for sale (and which was initially designated for development of commercial centers).

¹ As part of Gamida’s PR, reference was made to additional information about the studies through the TCT Meetings of ASBMT and CIBMTR website:

https://tct.confex.com/tct/2019/meetingapp.cgi/Paper/13531

https://tct.confex.com/tct/2019/meetingapp.cgi/Paper/13352

https://tct.confex.com/tct/2019/meetingapp.cgi/Paper/12685

For Further Information:

Company Contact

Ron Hadassi

CEO and Chairman of the Board of Directors

Tel: +972-3-608-6048
Fax: +972-3-608-6050

ron@elbitimaging.com